Table 1.
Characteristics of patients and their response to Sur-AS-ODN ex vivo
| Patient no. | Sample source | Blast count | WBC count, ×109/L | Survivin level | Survivin decrease, % | CFU decrease, % | Previous treatments (responses) |
|---|---|---|---|---|---|---|---|
| 1 | BM | 63 | 27.4 | ND | 76.3 | 50 | Imatinib + decitabine (CR then relapse); AMN107 (resistant) |
| 2 | BM | 94 | 51 | 0.5 | 74.2 | 51.9 | Hydrea for 4 y (turned to BC); imatinib (400-800 g) |
| 3 | BM | 51 | 145 | 0.34 | 54.9 | 48 | Hydrea (—) |
| 4 | BM | 83 | 45.4 | ND | 82.7 | 7.8 | Hydrea (relapsed); interferon (intolerance); imatinib (no response); triapine + flurdarabine (side effect, stopped); hydrea + cyclophosphamide (no response); AMN107 (no response, dead) |
| 5 | BM | 84 | 51.8 | 1.93 | 71.5 | 38.2 | Hydrea (turned to BC) |
The baseline survivin protein levels are shown relative to those in KBM5 cells. The percent survivin decrease represents inhibition of survivin protein level by Sur-AS-ODN as compared to Sur-NS-ODN. The percent CFU decrease is inhibition of colony formation by Sur-AS-ODN as compared to Sur-NS-ODN.
BM indicates bone marrow; ND, not determined due to limited sample size; CR, complete response; BC, blast crisis.